Stephan Grupp on Muck Rack

Stephan Grupp

Havertown, Philadelphia
As seen in: Nature, Science Magazine, The Lancet, HemOnc Today, Cancer Discovery, The Journal of Immunology, Future Medicine, OncLive, BioCentury, Targeted Oncology
#CARTCell expert, bone marrow transplanter, pediatric oncologist, husband to my vastly better half. All opinions my own, not an investor. RT not=endorsement🌊🌊
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stephan

Contact Stephan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells - Nature Biomedical Engineering

|
By Tomasz M. Grzywa, Anna Romanov, Ryan Tannir, Duncan M. Morgan, Elisa Bergaggio, Stephan Kadauke, Luca Paruzzo, Marco Ruella, Stephan Grupp, Roberto Chiarle, K. Dane Wittrup, Leyuan Ma
| Nature
Abstract Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B cell malignancies, but many patients relapse owing to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (amph-vax).
Open in Who Shared Issue with article?

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies - Nature Communications

|
By Pablo Domizi, Jolanda Sarno, Sean A. Yamada-Hunter, Reema Baskar, Sean C. Bendall, Charles G. Mullighan, Ash A. Alizadeh, Hao-Wei Wang, Nirali Shah, Robbie G. Majzner, Crystal L. Mackall, Stephan Grupp, Elena Sotillo
| Nature
Abstract Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL). To identify tumor-intrinsic factors driving antigen loss, we perform single-cell analyses on 61 B-ALL patient samples treated with CAR T cells. Here we show that low levels of IKAROS in pro-B-like B-ALL cells before CAR T treatment correlate with antigen escape.
Open in Who Shared Issue with article?

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks - Nature Reviews Clinical Oncology

|
By Stephan Grupp
| Nature
Abstract Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, conferring durable and sometimes curative responses in patients with advanced-stage disease.
Open in Who Shared Issue with article?
See all 20 licensed articles (22 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Stephan

Contact Stephan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified